These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37197527)

  • 1. C-reactive protein and lactate dehydrogenase serum levels potentially predict the response to checkpoint inhibitors in patients with advanced non-small cell lung cancer.
    Wei Y; Xu J; Huang X; Xie S; Lin P; Wang C; Guo Y; Zou S; Zhao Z; Wen W; Song Y; Bao Z; Zhang L; Liu W; Kong W; Wang W; He B; Zhang S; Zhou C; Chen Y; Yu Z
    J Thorac Dis; 2023 Apr; 15(4):1892-1900. PubMed ID: 37197527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer.
    Diker O; Olgun P; Balyemez U; Sigit Ikiz S
    Cureus; 2023 Jan; 15(1):e33234. PubMed ID: 36733552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors.
    Chen X; Li Z; Zhou J; Wei Q; Wang X; Jiang R
    PeerJ; 2022; 10():e14566. PubMed ID: 36540802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 6. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer.
    Oya Y; Yoshida T; Kuroda H; Mikubo M; Kondo C; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Oncotarget; 2017 Nov; 8(61):103117-103128. PubMed ID: 29262550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
    Akamine T; Takada K; Toyokawa G; Kinoshita F; Matsubara T; Kozuma Y; Haratake N; Takamori S; Hirai F; Tagawa T; Okamoto T; Yoneshima Y; Okamoto I; Shimokawa M; Oda Y; Nakanishi Y; Maehara Y
    Surg Oncol; 2018 Mar; 27(1):88-94. PubMed ID: 29549910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis.
    Zhang Q; Gong X; Sun L; Miao L; Zhou Y
    Front Oncol; 2022; 12():791496. PubMed ID: 35924149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
    Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
    Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of Lactate Dehydrogenase in Second-Line Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma.
    Li Y; Wang K; Zhao E; Li B; Li S; Dong X; Yuan L; Yang H
    Pathol Oncol Res; 2022; 28():1610245. PubMed ID: 35721326
    [No Abstract]   [Full Text] [Related]  

  • 11. Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin.
    Qiu Y; Jiang J; Zhang M; Qin Y
    Oncol Lett; 2019 Jul; 18(1):161-168. PubMed ID: 31289485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.
    Wang X; Zhang B; Chen X; Mo H; Wu D; Lan B; Li Q; Xu B; Huang J
    Thorac Cancer; 2019 Jun; 10(6):1395-1401. PubMed ID: 31017739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.
    Minichsdorfer C; Gleiss A; Aretin MB; Schmidinger M; Fuereder T
    Ann Med; 2022 Dec; 54(1):1339-1349. PubMed ID: 35535695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
    Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
    JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
    Riedl JM; Barth DA; Brueckl WM; Zeitler G; Foris V; Mollnar S; Stotz M; Rossmann CH; Terbuch A; Balic M; Niedrist T; Bertsch T; Stoeger H; Pichler M; Olschewski H; Absenger G; Ficker JH; Gerger A; Posch F
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy.
    Inomata M; Hirai T; Seto Z; Tokui K; Taka C; Okazawa S; Kambara K; Ichikawa T; Imanishi S; Yamada T; Miwa T; Hayashi R; Tobe K
    Pathol Oncol Res; 2020 Jan; 26(1):327-333. PubMed ID: 30232703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC.
    Li B; Li C; Guo M; Shang S; Li X; Xie P; Sun X; Yu J; Wang L
    Onco Targets Ther; 2018; 11():6287-6294. PubMed ID: 30310292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy.
    Sung M; Jang WS; Kim HR; Park JA; Lim SM; Kim HR; Cho BC; Park YR; Hong MH
    Transl Lung Cancer Res; 2023 Jul; 12(7):1506-1516. PubMed ID: 37577328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer.
    Tjokrowidjaja A; Lord SJ; John T; Lewis CR; Kok PS; Marschner IC; Lee CK
    Cancer; 2022 Apr; 128(8):1574-1583. PubMed ID: 35090047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment Serum Lactate Dehydrogenase and Metastases Numbers as Potential Determinants of Anti-PD-1 Therapy Outcome in Nasopharyngeal Carcinoma.
    Ali WAS; Huang X; Wu Y; Ma Y; Pan H; Liao J; Yang Z; Hong S; Yang Y; Huang Y; Zhao Y; Fang W; Zhao H; Zhang L
    Cancer Control; 2023; 30():10732748221148912. PubMed ID: 36592162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.